Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD)

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

August 9, 2019

Primary Completion Date

January 28, 2021

Study Completion Date

January 28, 2021

Conditions
Facioscapulohumeral Muscular Dystrophy (FSHD)
Interventions
DRUG

Losmapimod oral tablet

Losmapimod will be administered with food when possible.

DRUG

Placebo oral tablet

Placebo will be administered with food when possible

Trial Locations (17)

14642

University of Rochester Medical Center, Rochester

21205

Kennedy Krieger Institute, Baltimore

23298

Virginia Commonwealth University, Richmond

32610

University of Florida, Gainesville

43221

Ohio State University, Columbus

46026

Hospital UiP La Fe, Valencia

63110

Washington University School of Medicine, St Louis

66160

University of Kansas Medical Center, Kansas City

84132

University of Utah, Salt Lake City

90095

University of California Los Angeles (UCLA), Los Angeles

92868

University of California Irvine, Irvine

98195

University of Washinton Medical Center, Seattle

01655

University of Massachusetts Memorial Medical Center, Worcester

K1Y 4E9

Ottawa Hospital Research Institute, Ottawa

H3A 2B4

Montreal Neurological Institute and Hospital, Montreal

06001

CHU de NICE- CHU pasteur2, Nice

08041

Hospital de la Sta Creu i St Pau, Barcelona

Sponsors
All Listed Sponsors
lead

Fulcrum Therapeutics

INDUSTRY